Addressing Unmet Needs in Multiple Myeloma Research

Published on: June 11, 2024


Sanofi researcher in a lab
Despite significant advancements in multiple myeloma treatment, new solutions are desperately needed to improve long-term outcomes, particularly for newly diagnosed and transplant-ineligible patients.

Multiple myeloma (MM) research has seen a number of new developments over recent years, yet it remains incurable with an estimated 52% five-year survival rate for newly diagnosed patients. Complicating matters, MM is most commonly diagnosed in people over age 65, when frailty or certain comorbidities may exclude them from common treatment regimens and procedures, such as a bone marrow transplant. But regardless of age or prior health status, the frequent prospect of relapse, requiring multiple cycles and types of therapy, remains the most consistent issue for care.

Because MM is a complex disease, there is a crucial need for new solutions to address common treatment challenges across different lines of therapy. By harnessing the power of the immune system, immuno-science researchers are exploring novel mechanisms, targets, technologies and differentiated combinations that may one day overcome these barriers and make a meaningful difference in MM treatment outcomes.

Zandra Klippel, Global Product Head, Multiple Myeloma, discusses the MM treatment landscape and Sanofi’s dedication to progressing scientific innovation to help people with MM.

In multiple myeloma, researchers are exploring a type of immunotherapy known as monoclonal antibodies, which are designed to target specific epitopes on MM cells. Targeting these epitopes could potentially induce an immune response and activate the immune system to detect and attack cancerous cells.

Recent data, including MM research presented at the 2024 American Society for Clinical Oncology (ASCO) and the European Hematology Society (EHA) annual meetings, have focused on monoclonal antibodies targeting one epitope known as CD38, a protein highly and uniformly expressed on the surface of MM cells. These data speak not only to Sanofi’s significant progress in advancing MM research, but also our scientific partnerships and the work we’re doing to improve outcomes for patients.

Our heavy focus in this subspecialty of cancer research can drive us to make a big impact in MM research. We are fueled by our ambition to find solutions for one of the most difficult-to-treat cancers and remain committed to building and delivering on our goal of advancing oncology innovation.



  • Zhang N, Wu J, Wang Q, et al. Global burden of hematologic malignancies and evolution patterns over the past 30 years. Blood Cancer J. 2023;13(1):1-13. doi:10.1038/s41408-023-00853-3
  • Fonseca, R., Usmani, S.Z., Mehra, M. et al. Frontline treatment patterns and attrition rates by subsequent lines of therapy in patients with newly diagnosed multiple myeloma. BMC Cancer. 2020: 20(1087).
  • Pawlyn C, Cairns DA, Menzies T, et al. Autologous stem cell transplantation is safe and effective for fit, older myeloma patients: exploratory results from the Myeloma XI trial. Haematologica. 2020;107(1):231-242. doi:10.3324/haematol.2020.262360